Accord Drug Patent Portfolio
Accord owns 1 orange book drug protected by 5 US patents Given below is the list of Accord's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11717555 | Pharmaceutical compositions having a selected release duration | 01 Jan, 2039 | Active |
| US12133878 | Pharmaceutical compositions having a selected release duration | 18 Dec, 2037 | Active |
| US10646572 | Pharmaceutical compositions with enhanced stability | 16 Jan, 2027 | Active |
| US9572857 | Pharmaceutical compositions with enhanced stability | 16 Jan, 2027 | Active |
| US9744207 | Pharmaceutical compositions with enhanced stability | 16 Jan, 2027 | Active |
Latest Legal Activities on Accord's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Accord.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US10646572 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9572857 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9744207 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US10646572 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9572857 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9744207 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2023 | US10646572 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 19 Oct, 2023 | US10646572 |
|
Email Notification
Critical
| 08 Aug, 2023 | US11717555 |
| Mail Patent eGrant Notification | 08 Aug, 2023 | US11717555 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 08 Aug, 2023 | US11717555 |
| Recordation of Patent eGrant | 08 Aug, 2023 | US11717555 |
| Patent eGrant Notification | 08 Aug, 2023 | US11717555 |
|
Electronic Review
Critical
| 08 Aug, 2023 | US11717555 |
|
Recordation of Patent Grant Mailed
Critical
| 08 Aug, 2023 | US11717555 |
Accord's Family Patents
Recent FDA approvals and tentative approvals for Accord
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Paliperidone Palmitate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 16 May, 2025 |
| Brexpiprazole |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 17 Aug, 2021 |
| Perampanel |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 08 Jun, 2021 |
Accord Drug List
Given below is the complete list of Accord's drugs and the patents protecting them.
1. Camcevi Kit
Camcevi Kit is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11717555 | Pharmaceutical compositions having a selected release duration |
01 Jan, 2039
(13 years from now)
| Active |
| US12133878 | Pharmaceutical compositions having a selected release duration |
18 Dec, 2037
(11 years from now)
| Active |
| US10646572 | Pharmaceutical compositions with enhanced stability |
16 Jan, 2027
(1 year, 16 days from now)
| Active |
| US9572857 | Pharmaceutical compositions with enhanced stability |
16 Jan, 2027
(1 year, 16 days from now)
| Active |
| US9744207 | Pharmaceutical compositions with enhanced stability |
16 Jan, 2027
(1 year, 16 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Camcevi Kit's drug page